Treatment of Multiple Myeloma: Best Practices from Levine Cancer Institute and Satellites : Episode 12
RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM
An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.
EP: 1.The Role of Transplant in Newly Diagnosed Multiple Myeloma
EP: 2.Treatment Options for Patients With Newly Diagnosed Multiple Myeloma
EP: 3.Multiple Myeloma: Data on Outcomes Based On Cytogenetics
EP: 4.Transplant and Treatment Decision-Making in Multiple Myeloma
EP: 5.Treatment Strategies for Patients With Transplant-Ineligible MM
EP: 6.Assessing Frailty in Multiple Myeloma
EP: 7.Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times
EP: 8.CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
EP: 9.MM: Influence of CAR T-Cell Therapy on Clinical Care
EP: 10.Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MM
EP: 11.Talquetamab for Patients With Relapsed/Refractory MM
Now Viewing
EP: 12.RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM
EP: 13.Patient Profile 1: A 70-Year-Old With Multiple Myeloma
EP: 14.Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease
EP: 15.Patient Profile 3: A 68-Year-Old With Multiple Myeloma
EP: 16.Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma
EP: 17.Multiple Myeloma Experts Discuss Treatment Options and New Advances
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
